Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

Genomic aberrations in cell cycle genes predict progression of KIT-mutant gastrointestinal stromal tumors (GISTs).

Heinrich MC, Patterson J, Beadling C, Wang Y, Debiec-Rychter M, Dewaele B, Corless CL, Duensing A, Raut CP, Rubin B, Ordog T, van de Rijn M, Call J, Mühlenberg T, Fletcher JA, Bauer S.

Clin Sarcoma Res. 2019 Mar 5;9:3. doi: 10.1186/s13569-019-0112-7. eCollection 2019.

2.

Economic Community of West African States Disaster Preparedness Tabletop Exercise: Building Regional Capacity to Enhance Health Security.

Morton Hamer MJ, Reed PL, Greulich JD, Beadling CW.

Disaster Med Public Health Prep. 2018 May 30:1-5. doi: 10.1017/dmp.2018.44. [Epub ahead of print]

PMID:
29843836
3.

Enhancing Global Health Security: US Africa Command's Disaster Preparedness Program.

Morton Hamer MJ, Reed PL, Greulich JD, Beadling CW.

Disaster Med Public Health Prep. 2019 Apr;13(2):319-329. doi: 10.1017/dmp.2018.17. Epub 2018 Mar 7.

PMID:
29510765
4.

Liberia national disaster preparedness coordination exercise: Implementing lessons learned from the West African disaster preparedness initiative.

Hamer MJM, Reed PL, Greulich JD, Beadling CW.

Am J Disaster Med. 2017 Winter;12(1):35-41. doi: 10.5055/ajdm.2017.0256.

PMID:
28822213
5.

Biochemical, Molecular, and Clinical Characterization of Succinate Dehydrogenase Subunit A Variants of Unknown Significance.

Bannon AE, Kent J, Forquer I, Town A, Klug LR, McCann K, Beadling C, Harismendy O, Sicklick JK, Corless C, Shinde U, Heinrich MC.

Clin Cancer Res. 2017 Nov 1;23(21):6733-6743. doi: 10.1158/1078-0432.CCR-17-1397. Epub 2017 Jul 19.

6.

Durable Response to Afatinib in Lung Adenocarcinoma Harboring NRG1 Gene Fusions.

Gay ND, Wang Y, Beadling C, Warrick A, Neff T, Corless CL, Tolba K.

J Thorac Oncol. 2017 Aug;12(8):e107-e110. doi: 10.1016/j.jtho.2017.04.025. Epub 2017 May 10. No abstract available.

7.

MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation.

Schaefer IM, Wang Y, Liang CW, Bahri N, Quattrone A, Doyle L, Mariño-Enríquez A, Lauria A, Zhu M, Debiec-Rychter M, Grunewald S, Hechtman JF, Dufresne A, Antonescu CR, Beadling C, Sicinska ET, van de Rijn M, Demetri GD, Ladanyi M, Corless CL, Heinrich MC, Raut CP, Bauer S, Fletcher JA.

Nat Commun. 2017 Mar 8;8:14674. doi: 10.1038/ncomms14674.

8.

The West Africa Disaster Preparedness Initiative: Strengthening National Capacities for All-Hazards Disaster Preparedness.

Morton Hamer MJ, Reed PL, Greulich JD, Kelen GD, Bradstreet NA, Beadling CW.

Disaster Med Public Health Prep. 2017 Aug;11(4):431-438. doi: 10.1017/dmp.2016.155. Epub 2016 Nov 24.

PMID:
27881208
9.

Zika Virus: A Review of Management Considerations and Controversies at Six Months.

Singer L, Vest KG, Beadling CW.

Disaster Med Public Health Prep. 2017 Jun;11(3):279-284. doi: 10.1017/dmp.2016.141. Epub 2016 Aug 30.

PMID:
27572275
10.

Republic of Senegal Disaster Preparedness and Response Exercise: Lessons Learned and Progress Toward Key Goals.

Morton Hamer MJ, Jordan JJ, Reed PL, Greulich JD, Gaye DB, Beadling CW.

Disaster Med Public Health Prep. 2017 Apr;11(2):183-189. doi: 10.1017/dmp.2016.113. Epub 2016 Jul 27.

PMID:
27460434
11.

A Multiplexed Amplicon Approach for Detecting Gene Fusions by Next-Generation Sequencing.

Beadling C, Wald AI, Warrick A, Neff TL, Zhong S, Nikiforov YE, Corless CL, Nikiforova MN.

J Mol Diagn. 2016 Mar;18(2):165-75. doi: 10.1016/j.jmoldx.2015.10.002. Epub 2015 Dec 30.

PMID:
26747586
12.

Ebola Virus and Public Health (Part 2). Introduction.

Beadling CW, Burkle FM Jr, Koenig KL, Sharp TW.

Disaster Med Public Health Prep. 2015 Oct;9(5):521. No abstract available.

PMID:
26668864
13.

Utility of BRAF V600E mutation-specific immunohistochemistry in detecting BRAF V600E-mutated gastrointestinal stromal tumors.

Patil DT, Ma S, Konishi M, Carver PD, Pukay M, Beadling C, Corless CL, Rubin BP.

Am J Clin Pathol. 2015 Nov;144(5):782-9. doi: 10.1309/AJCPRK3V2EIIUPQZ.

PMID:
26486743
14.

Ebola virus and public health.

Beadling CW, Burkle FM Jr, Koenig KL, Sharp TW.

Disaster Med Public Health Prep. 2015 Feb;9(1):31. No abstract available.

PMID:
25901336
15.

Novel mutations in neuroendocrine carcinoma of the breast: possible therapeutic targets.

Ang D, Ballard M, Beadling C, Warrick A, Schilling A, O'Gara R, Pukay M, Neff TL, West RB, Corless CL, Troxell ML.

Appl Immunohistochem Mol Morphol. 2015 Feb;23(2):97-103. doi: 10.1097/PDM.0b013e3182a40fd1.

PMID:
25679062
16.

Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.

Lopez-Chavez A, Thomas A, Rajan A, Raffeld M, Morrow B, Kelly R, Carter CA, Guha U, Killian K, Lau CC, Abdullaev Z, Xi L, Pack S, Meltzer PS, Corless CL, Sandler A, Beadling C, Warrick A, Liewehr DJ, Steinberg SM, Berman A, Doyle A, Szabo E, Wang Y, Giaccone G.

J Clin Oncol. 2015 Mar 20;33(9):1000-7. doi: 10.1200/JCO.2014.58.2007. Epub 2015 Feb 9.

17.

Assessing copy number alterations in targeted, amplicon-based next-generation sequencing data.

Grasso C, Butler T, Rhodes K, Quist M, Neff TL, Moore S, Tomlins SA, Reinig E, Beadling C, Andersen M, Corless CL.

J Mol Diagn. 2015 Jan;17(1):53-63. doi: 10.1016/j.jmoldx.2014.09.008. Epub 2014 Nov 7.

18.

Next generation sequencing in clinical diagnostics: experiences of early adopters.

Lyon E, Cockerill FR 3rd, Bale SJ, Beadling C, Bry L, Hagenkord J, Kulkarni S, Press R, Palomaki GE.

Clin Chem. 2015 Jan;61(1):41-9. doi: 10.1373/clinchem.2014.222687. Epub 2014 Nov 24. No abstract available.

19.

Combination therapy for KIT-mutant mast cells: targeting constitutive NFAT and KIT activity.

Macleod AC, Klug LR, Patterson J, Griffith DJ, Beadling C, Town A, Heinrich MC.

Mol Cancer Ther. 2014 Dec;13(12):2840-51. doi: 10.1158/1535-7163.MCT-13-0830. Epub 2014 Sep 24.

20.

International Symposium on Disaster Medicine and Public Health Management: review of the Hyogo framework for action.

Egawa S, MacIntyre AG, Beadling CW, Walsh JT, Shimomura O.

Disaster Med Public Health Prep. 2014 Aug;8(4):357-8. doi: 10.1017/dmp.2014.85. No abstract available.

PMID:
25231470
21.

The 2015 Hyogo Framework for Action: cautious optimism.

Burkle FM Jr, Egawa S, MacIntyre AG, Otomo Y, Beadling CW, Walsh JT.

Disaster Med Public Health Prep. 2014 Jun;8(3):191-2. doi: 10.1017/dmp.2014.50. Epub 2014 Jun 13. No abstract available.

PMID:
24923725
22.

Oncogenic mutations in melanomas and benign melanocytic nevi of the female genital tract.

Tseng D, Kim J, Warrick A, Nelson D, Pukay M, Beadling C, Heinrich M, Selim MA, Corless CL, Nelson K.

J Am Acad Dermatol. 2014 Aug;71(2):229-36. doi: 10.1016/j.jaad.2014.03.033. Epub 2014 May 17.

23.

Mutation profiling in gallbladder cancer in Indian population.

Kumari N, Corless CL, Warrick A, Beadling C, Nelson D, Neff T, Krishnani N, Kapoor VK.

Indian J Pathol Microbiol. 2014 Jan-Mar;57(1):9-12. doi: 10.4103/0377-4929.130849.

24.

KRAS and KIT Gatekeeper Mutations Confer Polyclonal Primary Imatinib Resistance in GI Stromal Tumors: Relevance of Concomitant Phosphatidylinositol 3-Kinase/AKT Dysregulation.

Serrano C, Wang Y, Mariño-Enríquez A, Lee JC, Ravegnini G, Morgan JA, Bertagnolli MM, Beadling C, Demetri GD, Corless CL, Heinrich MC, Fletcher JA.

J Clin Oncol. 2015 Aug 1;33(22):e93-6. doi: 10.1200/JCO.2013.48.7488. Epub 2014 Mar 31. No abstract available.

25.

Genetic profiling to determine risk of relapse-free survival in high-risk localized prostate cancer.

Barnett CM, Heinrich MC, Lim J, Nelson D, Beadling C, Warrick A, Neff T, Higano CS, Garzotto M, Qian D, Corless CL, Thomas GV, Beer TM.

Clin Cancer Res. 2014 Mar 1;20(5):1306-12. doi: 10.1158/1078-0432.CCR-13-1775. Epub 2013 Dec 18.

26.

Frequent PIK3CA mutations in radial scars.

Wolters KL, Ang D, Warrick A, Beadling C, Corless CL, Troxell ML.

Diagn Mol Pathol. 2013 Dec;22(4):210-4. doi: 10.1097/PDM.0b013e318288b346.

PMID:
24193002
27.

Frequent phosphatidylinositol-3-kinase mutations in proliferative breast lesions.

Ang DC, Warrick AL, Shilling A, Beadling C, Corless CL, Troxell ML.

Mod Pathol. 2014 May;27(5):740-50. doi: 10.1038/modpathol.2013.197. Epub 2013 Nov 1.

28.

A review of the role of the U.S. military in nonemergency health engagement.

Baxter M, Beadling C.

Mil Med. 2013 Nov;178(11):1231-40. doi: 10.7205/MILMED-D-13-00014. Review.

PMID:
24183772
29.

Gene expression of the IGF pathway family distinguishes subsets of gastrointestinal stromal tumors wild type for KIT and PDGFRA.

Beadling C, Patterson J, Justusson E, Nelson D, Pantaleo MA, Hornick JL, Chacón M, Corless CL, Heinrich MC.

Cancer Med. 2013 Feb;2(1):21-31. doi: 10.1002/cam4.57. Epub 2013 Feb 3.

30.

Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.

Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R, Weber JS, Gajewski TF, O'Day SJ, Kim KB, Lawrence D, Flaherty KT, Luke JJ, Collichio FA, Ernstoff MS, Heinrich MC, Beadling C, Zukotynski KA, Yap JT, Van den Abbeele AD, Demetri GD, Fisher DE.

J Clin Oncol. 2013 Sep 10;31(26):3182-90. doi: 10.1200/JCO.2012.47.7836. Epub 2013 Jun 17.

31.

MDM2 Amplification and PI3KCA Mutation in a Case of Sclerosing Rhabdomyosarcoma.

Kikuchi K, Wettach GR, Ryan CW, Hung A, Hooper JE, Beadling C, Warrick A, Corless CL, Olson SB, Keller C, Mansoor A.

Sarcoma. 2013;2013:520858. doi: 10.1155/2013/520858. Epub 2013 May 20.

32.

Cross-cultural communication capabilities of U.S. military trainers: host nation perspective.

Mahmood M, Alameri A, Jawad S, Alani Y, Zuerlein S, Nakano G, Anderson W, Beadling C.

Mil Med. 2013 Jun;178(6):631-7. doi: 10.7205/MILMED-D-12-00339.

PMID:
23756069
33.

Novel method for PIK3CA mutation analysis: locked nucleic acid--PCR sequencing.

Ang D, O'Gara R, Schilling A, Beadling C, Warrick A, Troxell ML, Corless CL.

J Mol Diagn. 2013 May;15(3):312-8. doi: 10.1016/j.jmoldx.2012.12.005. Epub 2013 Mar 27.

PMID:
23541593
34.

BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance.

Falchook GS, Trent JC, Heinrich MC, Beadling C, Patterson J, Bastida CC, Blackman SC, Kurzrock R.

Oncotarget. 2013 Feb;4(2):310-5.

35.

PIK3CA-AKT pathway mutations in micropapillary breast carcinoma.

Flatley E, Ang D, Warrick A, Beadling C, Corless CL, Troxell ML.

Hum Pathol. 2013 Jul;44(7):1320-7. doi: 10.1016/j.humpath.2012.10.018. Epub 2013 Jan 24.

PMID:
23352210
36.

Combining highly multiplexed PCR with semiconductor-based sequencing for rapid cancer genotyping.

Beadling C, Neff TL, Heinrich MC, Rhodes K, Thornton M, Leamon J, Andersen M, Corless CL.

J Mol Diagn. 2013 Mar;15(2):171-6. doi: 10.1016/j.jmoldx.2012.09.003. Epub 2012 Dec 27.

PMID:
23274167
37.

Cytokine-mediated programmed proliferation of virus-specific CD8(+) memory T cells.

Raué HP, Beadling C, Haun J, Slifka MK.

Immunity. 2013 Jan 24;38(1):131-9. doi: 10.1016/j.immuni.2012.09.019. Epub 2012 Dec 20.

38.

Biphasic papillary and lobular breast carcinoma with PIK3CA and IDH1 mutations.

Ang D, VanSandt AM, Beadling C, Warrick A, West RB, Corless CL, Troxell ML.

Diagn Mol Pathol. 2012 Dec;21(4):221-4. doi: 10.1097/PDM.0b013e31826ddbd1.

PMID:
23111200
39.

Multiplex mutation screening by mass spectrometry in gastrointestinal stromal tumours.

Kang G, Lee J, Jang KT, Beadling C, Corless CL, Heinrich MC, Park JO, Kang WK, Park CK, Kim KM.

Pathology. 2012 Aug;44(5):460-4. doi: 10.1097/PAT.0b013e3283559c45.

PMID:
22777070
40.

Mucinous breast carcinomas lack PIK3CA and AKT1 mutations.

Kehr EL, Jorns JM, Ang D, Warrick A, Neff T, Degnin M, Lewis R, Beadling C, Corless CL, Troxell ML.

Hum Pathol. 2012 Dec;43(12):2207-12. doi: 10.1016/j.humpath.2012.03.012. Epub 2012 Jun 15.

PMID:
22705004
41.

Multiplex high-throughput gene mutation analysis in acute myeloid leukemia.

Dunlap J, Beadling C, Warrick A, Neff T, Fleming WH, Loriaux M, Heinrich MC, Kovacsovics T, Kelemen K, Leeborg N, Gatter K, Braziel RM, Press R, Corless CL, Fan G.

Hum Pathol. 2012 Dec;43(12):2167-76. doi: 10.1016/j.humpath.2012.03.002. Epub 2012 Jun 1.

PMID:
22658276
42.

Phosphatidylinositol-3-kinase pathway mutations are common in breast columnar cell lesions.

Troxell ML, Brunner AL, Neff T, Warrick A, Beadling C, Montgomery K, Zhu S, Corless CL, West RB.

Mod Pathol. 2012 Jul;25(7):930-7. doi: 10.1038/modpathol.2012.55. Epub 2012 Mar 30.

43.

Newly described activating JAK3 mutations in T-cell acute lymphoblastic leukemia.

Bains T, Heinrich MC, Loriaux MM, Beadling C, Nelson D, Warrick A, Neff TL, Tyner JW, Dunlap J, Corless CL, Fan G.

Leukemia. 2012 Sep;26(9):2144-6. doi: 10.1038/leu.2012.74. Epub 2012 Mar 19. No abstract available.

PMID:
22425895
44.

BRAF and KRAS mutations in sporadic glomus tumors.

Chakrapani A, Warrick A, Nelson D, Beadling C, Corless CL.

Am J Dermatopathol. 2012 Jul;34(5):533-5. doi: 10.1097/DAD.0b013e31823931b4.

PMID:
22317887
45.

Global health language and culture competency.

Beadling C, Maza J, Nakano G, Mahmood M, Jawad S, Al-Ameri A, Zuerlein S, Anderson W.

J Spec Oper Med. 2012 Winter;12(4):10-6.

PMID:
23536451
46.

RAS mutations in therapy-related acute myeloid leukemia after successful treatment of acute promyelocytic leukemia.

Kelemen K, Kovacsovics T, Braziel R, Corless C, Beadling C, Fan G.

Leuk Lymphoma. 2012 May;53(5):999-1002. doi: 10.3109/10428194.2011.634047. Epub 2011 Dec 7. No abstract available.

PMID:
22035377
47.

A new paradigm for military humanitarian medical operations: mission-generic metrics.

Waller SG, Ward JB, Montalvo M, Cunliffe C, Beadling C, Riley K.

Mil Med. 2011 Aug;176(8):845-51.

PMID:
21882771
48.

Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry.

Beadling C, Heinrich MC, Warrick A, Forbes EM, Nelson D, Justusson E, Levine J, Neff TL, Patterson J, Presnell A, McKinley A, Winter LJ, Dewey C, Harlow A, Barney O, Druker BJ, Schuff KG, Corless CL.

J Mol Diagn. 2011 Sep;13(5):504-13. doi: 10.1016/j.jmoldx.2011.04.003. Epub 2011 Jul 2. Erratum in: J Mol Diagn. 2012 Jul;14(4):418.

49.

Immunohistochemical and molecular markers in breast phyllodes tumors.

Korcheva VB, Levine J, Beadling C, Warrick A, Countryman G, Olson NR, Heinrich MC, Corless CL, Troxell ML.

Appl Immunohistochem Mol Morphol. 2011 Mar;19(2):119-25. doi: 10.1097/PAI.0b013e3181f5349a.

PMID:
21030860
50.

MET receptor sequence variants R970C and T992I lack transforming capacity.

Tyner JW, Fletcher LB, Wang EQ, Yang WF, Rutenberg-Schoenberg ML, Beadling C, Mori M, Heinrich MC, Deininger MW, Druker BJ, Loriaux MM.

Cancer Res. 2010 Aug 1;70(15):6233-7. doi: 10.1158/0008-5472.CAN-10-0429.

Supplemental Content

Loading ...
Support Center